4beta-hydroxycholesterol in Cirrhosis

NCT ID: NCT04199910

Last Updated: 2024-05-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

SUSPENDED

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-12-01

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim is to evaluate the levels of oxysterols and especially 4beta-hydroxycholesterol in patients with liver cirrhosis. Three cirrhosis cohorts are recruited: patients treated with spironolactone, patients treated with rifaximin, patients without spironolactone or rifaximin. Also three other control cohorts are recruited: patients with pneumonia, patients with Crohn's disease, patients with ulcerative colitis. The effect of the cirrhosis and its medications spironolactone and rifaximin are compared to control groups.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cirrhosis, Liver

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Liver cirrhosis with spironolactone

There is no intervention, only research blood samples are collected

Intervention Type OTHER

Research blood samples collected

Liver cirrhosis with rifaximin

There is no intervention, only research blood samples are collected

Intervention Type OTHER

Research blood samples collected

Liver cirrhosis without spironolactone or rifaximin

There is no intervention, only research blood samples are collected

Intervention Type OTHER

Research blood samples collected

Pneumonia

There is no intervention, only research blood samples are collected

Intervention Type OTHER

Research blood samples collected

Crohn's disease

There is no intervention, only research blood samples are collected

Intervention Type OTHER

Research blood samples collected

Ulcerative colitis

There is no intervention, only research blood samples are collected

Intervention Type OTHER

Research blood samples collected

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

There is no intervention, only research blood samples are collected

Research blood samples collected

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with cirrhosis, pneumonia, Crohn's disease or colitis ulcerosa
* Treated in the ward 42 of the Oulu University Hospital

Exclusion Criteria

* None
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Oulu

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Janne Hukkanen

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Janne Hukkanen, MD

Role: PRINCIPAL_INVESTIGATOR

Oulu University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Oulu University Hospital

Oulu, , Finland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Finland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

4bHC kirroosissa

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.